New hope for lung cancer patients who stopped responding to standard treatment
NCT ID NCT07315113
Summary
This early-stage study is testing whether adding an experimental drug called NXP900 to a standard lung cancer medication (osimertinib) can help control advanced lung cancer that has started growing again. The trial will enroll about 18 adults whose cancer has a specific genetic change (EGFR mutation) and who previously took osimertinib. Researchers will primarily check if the combination is safe and whether it can shrink tumors or stop them from growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR MUTATION POSITIVE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Massachusetts General Hospital
NOT_YET_RECRUITINGBoston, Massachusetts, 02114, United States
-
NEXT Houston
RECRUITINGHouston, Texas, 77054, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.